Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03554109
Title QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors NantKwest, Inc.
Indications

triple-receptor negative breast cancer

Therapies

Aldoxorubicin + ALT-803 + Avelumab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel

Cyclophosphamide + Doxorubicin + Paclitaxel

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.